Core Insights - Ailux, a wholly-owned subsidiary of Jingtai Technology, has entered into a multi-target strategic cooperation and platform licensing agreement with Eli Lilly, with a total value of up to $345 million [1] - This collaboration follows a previous partnership in which the two companies agreed on a $250 million AI small molecule drug collaboration [1] - Eli Lilly will leverage Ailux's proprietary platform to accelerate the discovery and development of bispecific antibodies and utilize its AI antibody research platform to enhance internal pipeline research [1] Company Highlights - The partnership signifies the recognition of Jingtai Technology's intelligent drug development platform in the AI antibody drug development space, particularly for new drug forms like bispecific antibodies [1] - Ailux, as a key focus of Jingtai Technology's large molecule drug development platform, has successfully served multiple international pharmaceutical companies and validated several research projects [1]